NRC — Preclinical in vivo facility
At a glance
- No Condition
- Open Date : November 14, 2019
- Manufacturing
- Professional, scientific and technical services
- National Research Council Canada
- Government of Canada
Overview
Eligibility criteria
Who is eligible
Biotechnology and biopharmaceutical companies can apply for the grant offered by the NRC's preclinical in vivo facility for the evaluation and functional characterization of biologics and vaccines.
Eligible expenses
The eligible expenses for this grant include:
- Validation of therapeutic targets and biomarkers for various diseases
- Evaluation of pharmacokinetics, pharmacodynamics, and brain penetration of biologics
- Vaccine uptake and distribution studies
- Efficacy studies in challenge models for infectious diseases and cancer vaccines
- Animal model development
- Development of novel imaging tools and methodologies
Eligible projects & activities
- Validation of therapeutic targets and biomarkers for cancer, infectious, inflammatory, and central nervous system (CNS) diseases - Evaluation of biomarker/target expression, pharmacokinetics, pharmacodynamics, and brain penetration of biologics in cell, tissue, and animal models - Vaccine uptake and distribution studies; evaluation of formulations for induction of immune response; response validation (antibody, cell-mediated, immune memory, functional assays) - Efficacy studies in challenge models for both infectious disease and cancer vaccines - Animal model development - Development of novel molecular imaging tools including nanocarriers and contrast agents; design of multi-modal targeting moieties on antibodies, peptides, and other proteins - Development of methodologies for cell, tissue, and whole-body imaging in small animals; guidance in the choice of imaging modality and combination of imaging modalities to provide enriched datasets
Evaluation & selection criteria
There are evaluation and selection criteria for this grant. The criteria include:
- Validation of therapeutic targets and biomarkers for specific diseases
- Evaluation of pharmacokinetics, pharmacodynamics, and brain penetration of biologics
- Assessment of vaccine uptake, distribution, and immune response induction
- Efficacy studies in challenge models for infectious disease and cancer vaccines
- Development of novel molecular imaging tools and methodologies
How to apply
- Step 1: Contact Shawn Makinen or Maria Moreno to express interest and discuss project details
- Step 2: Provide necessary documentation and project information for review
- Step 3: Work with NRC's preclinical in vivo specialists to finalize project scope and objectives
- Step 4: Review and agree on project timelines, deliverables, and budget
- Step 5: Collaborate with the NRC's team throughout the project duration
Additional information
- The NRC's preclinical in vivo facility provides expertise in cancer, infectious, inflammatory, and CNS diseases. - Evaluation includes biomarker/target expression, pharmacokinetics, pharmacodynamics, and brain penetration of biologics in various models. - Vaccine studies cover uptake, distribution, immune response induction, and efficacy in challenge models. - Animal model development and customization are available. - The facility offers state-of-the-art imaging tools, from optical to microCT and mass spectrometry. - Experienced in working with various animal species and specialized surgical procedures. - Behavioral testing capabilities include maze tests. - Access to a range of imaging systems and microscopy platforms for detailed analysis. - The team at the facility has over 25 years of experience and can help with IND applications. - Good Animal Practice certification and ethical review processes are in place. - The location of the facility is in Ottawa, Ontario, Canada.
Grant Summary
The NRC's preclinical in vivo facility offers comprehensive expertise and cutting-edge equipment for evaluating biologics and vaccines, enabling clients to validate their design approaches and assess preclinical safety and efficacy.
Detailed Explanation of the Grant
The NRC's preclinical in vivo facility, operated by the Human Health Therapeutics Research Centre, provides a wide range of capabilities to support the validation of therapeutic targets and biomarkers for various diseases. With over 25 years of experience, the facility specializes in evaluating biologics in cell, tissue, and animal models, conducting efficacy studies in infectious disease and cancer vaccines, and developing novel imaging tools for enhanced characterization.
Through state-of-the-art equipment and processes, including animal care certification, specialized surgical suites, and advanced imaging systems, the facility ensures high-quality research outcomes. Clients benefit from the facility's expertise in animal model development, formulation evaluation, and immune response studies, facilitating the generation of critical data for Investigational New Drug (IND) applications.
Collaborating with the NRC's preclinical in vivo specialists offers biotechnology and biopharmaceutical companies access to a dedicated team with a proven track record of success. The facility's commitment to Good Animal Practice and adherence to industry standards make it a trusted partner in validating biologics and vaccine designs, ultimately contributing to advancements in healthcare and therapeutic development.